Discover OCREVUS

Meet OCREVUS. An infusion treatment that's 2 times a year* for adults with relapsing or primary progressive forms of multiple sclerosis (MS).
*The first dose will be split between two
treatments, for a total of three treatments the first year.
Please read the Important Safety Information at bit.ly/OCRsafety and Prescribing Information at bit.ly/OCRPI.
OCREVUS is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and
active secondary progressive disease, and primary progressive MS. It is not known if OCREVUS is safe and effective in children.
OCREVUS can cause infusion reactions that can
be serious and require you to be hospitalized. OCREVUS increases your risk of getting certain infections, which can be life-threatening or cause death, including upper respiratory
tract infections, lower respiratory tract infections, skin infections and herpes infections. A rare brain infection called progressive multifocal leukoencephalopathy or PML that usually
leads to death or severe disability has been reported with OCREVUS. OCREVUS may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to
check your blood immunoglobulin levels. Additional serious side effects include the risk of cancers (malignancies), including breast cancer, and inflammation of the colon, or colitis.
These are not all the possible side effects of OCREVUS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA- 1088. You may also
report side effects to Genentech at [phone]. Learn more about OCREVUS by visiting bit.ly/2qnxqMm.